PDUFA action date is November 2, 2019.
If approved, Talicia would be eligible for eight years of U.S. market exclusivity.
Talicia (RHB-105) is an oral capsule combination of two antibiotics, rifabutin, and amoxicillin, and a proton pump inhibitor, omeprazole.
Shares are up 3% premarket.
Now read: RedHill Biopharma And Talicia: The NDA »
Subscribe for full text news in your inbox